PresentationI will now hand the conference over to your speaker host, Dan Faga, President and CEO of Anaptys. Please go ahead, sir.Good day. Thank you for standing by. Welcome to the Anaptys conference call. [Operator Instructions] Please note that today's conference may be recorded.Daniel FagaPresident, CEO & Director Good afternoon and thank you for joining us today. We are excited to discuss today the further evolution of Anaptys with our intention to separate our biopharma operations from our substantia ...

公司调查事件 - 律师事务所Bleichmar Fonti & Auld LLP宣布对MoonLake Immunotherapeutics涉嫌违反联邦证券法展开调查 [1] - 调查针对公司可能存在的证券违法行为 投资者可通过指定链接获取更多信息 [1][4] 公司业务与试验背景 - MoonLake为临床阶段生物技术公司 专注于治疗炎症性皮肤和关节疾病的疗法 [2] - 公司在相关期间进行了高度关注的sonelokimab药物三期VELA试验 针对中重度化脓性汗腺炎成人患者 [2] 临床试验结果与市场反应 - 2025年9月29日盘前 MoonLake公布VELA三期试验第16周结果 数据显示两项试验结果均未达预期 [3] - 试验结果引发对药物监管批准前景和商业可行性的质疑 [3] - 消息公布后公司股价单日暴跌55.75美元/股 跌幅达90% 从61.99美元/股跌至6.24美元/股 [3] 律师事务所背景 - BFA为国际领先的证券集体诉讼律师事务所 曾代表原告在特斯拉案中获9亿美元赔偿 在Teva制药案中获4.2亿美元赔偿 [6] - 该律所被Chambers USA、《法律500强》和ISS SCAS评为顶级原告律师事务所 [6]

Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 & 2) to be presented Sunday, October 5 at 5pm CEST PARIS, France – September 29, 2025 – 10:05 PM ...

WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that on September 25, 2025, the Compensation Committee of Cogent’s Board of Directors, made up entirely of independent directors, approved the grants of “inducement” equity awards to 10 new employees under the company’s 2020 Inducement Plan with a grant date of September 29, 2025. The ...

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces pricing of $4.8 million public offering. ...

PresentationLadies and gentlemen, thank you for standing by. Welcome to the BioLineRx Update Conference Call. [Operator Instructions] I would now like to turn over the call to Irina Koffler, Head of Investor Relations and Corporate Communications, BioLineRx. Please go ahead.Irina KofflerManaging Director Thank you, operator, and welcome, everyone. Thank you for joining us as we discuss this morning's announcement that BioLineRx and Hemispherian have established a joint venture. Earlier today, we issued a pr ...

公司核心业务 - 专注于开发创新癌症疗法 特别是双特异性抗体技术[1] - 主要竞争对手为Genmab A/S 目前正与该公司进行重大交易[1] 股价表现与估值 - 当前股价94.12美元 过去一年大幅上涨36.62%[3] - 股价区间在过去一年介于33.19美元至94.55美元之间[4] - 公司市值约71.2亿美元 显示其在生物技术领域的重要地位[4] - 今日交易量达1486万股 显示投资者兴趣浓厚[5] 并购交易进展 - Genmab A/S同意以每股97美元价格收购公司[2] - Wells Fargo设定97美元目标价 较当前股价存在2.69%上涨空间[2] - 当前股价94.46美元 接近收购报价水平[2] 交易合规性审查 - Halper Sadeh LLC正在调查97美元收购价对股东是否公平[3] - 调查重点在于公司董事会是否尽到对股东的受托责任[3] - 利益相关方密切关注以确保收购价格反映公司真实价值[5]

ORLANDO, FLORIDA / ACCESS Newswire / September 29, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based therapies, today announced its plan to conduct an Institutional Review Board (IRB) study that could fundamentally transform the cannabinoid edible and nutraceutical markets. The study is designed to demonstrate the dramatically enhanced efficacy of CBD-loaded exosomes in oral delivery. ...

TRENDING: Robinhood Leads 7 Top S&P 500 Stocks In 2025 Monday's IBD 50 Stocks To Watch pick, biotech leader Arcutis Biotherapeutics (ARQT), is breaking out past two buy points. That makes Arcutis stock one of the best stocks to watch right now. Arcutis Biotherapeutics develops dermatology treatments for unmet needs of immune-related skin diseases and conditions. Its main products approved by the U.S. Food and Drug Administration are Zoryve foam… Related news Stock Market Today: Dow Jones Wavers With Trump S ...

"Company†), a clinical-stage biotechnology company developing dermatology, wound care, and anti- infective therapies, today announced that it expects its common stock will begin trading on the Nasdaq Global Market under the ticker symbol "TTRX†on October 8, 2025. Copies of the prospectus, when available, may be obtained from Turn Therapeutics, 250 N. Westlake Blvd., Westlake Village, CA 91362. About Turn Therapeutics Tu. WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics ("Turn†or the ...